Quantum Capital Management LLC NJ Has $49.72 Million Position in IDEXX Laboratories, Inc. $IDXX

Key Points

• Quantum Capital Management LLC NJ cut its stake in IDEXX by 25.5% in Q3, selling 26,602 shares and now holds 77,825 shares worth $49.72 million, about 5.5% of the firm's portfolio and its 8th largest position.
• Significant insider selling occurred recently: CEO Jonathan Jay Mazelsky sold 23,326 shares for roughly $15.34 million (a 21.8% reduction in his ownership), and insiders sold a total of 45,957 shares worth about $29.86 million over the last quarter.
• Analysts have trimmed price targets but remain cautiously positive — the consensus rating is "Moderate Buy" with an average target of $783.33, while the stock trades near $608 with a 52-week range of $356.14–$769.98 and a PE of ~46.6.

Quantum Capital Management LLC NJ reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 25.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 77,825 shares of the company's stock after selling 26,602 shares during the period. IDEXX Laboratories accounts for approximately 5.5% of Quantum Capital Management LLC NJ's portfolio, making the stock its 8th largest position. Quantum Capital Management LLC NJ owned 0.10% of IDEXX Laboratories worth $49,722,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of IDXX. EverSource Wealth Advisors LLC raised its position in IDEXX Laboratories by 2.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company's stock valued at $397,000 after purchasing an additional 15 shares during the last quarter. STF Management LP grew its position in shares of IDEXX Laboratories by 1.3% in the 2nd quarter. STF Management LP now owns 1,240 shares of the company's stock worth $665,000 after buying an additional 16 shares during the last quarter. Clearstead Trust LLC grew its position in shares of IDEXX Laboratories by 1.1% in the 2nd quarter. Clearstead Trust LLC now owns 1,515 shares of the company's stock worth $813,000 after buying an additional 16 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its stake in shares of IDEXX Laboratories by 4.4% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company's stock valued at $243,000 after buying an additional 16 shares during the period. Finally, Moss Adams Wealth Advisors LLC increased its stake in shares of IDEXX Laboratories by 3.3% during the third quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company's stock valued at $337,000 after buying an additional 17 shares during the period. 87.84% of the stock is owned by institutional investors.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 23,326 shares of IDEXX Laboratories stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the completion of the transaction, the chief executive officer owned 83,606 shares in the company, valued at approximately $54,975,125.30. The trade was a 21.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Sophie V. Vandebroek sold 1,464 shares of the business's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the sale, the director directly owned 648 shares in the company, valued at $407,345.76. This trade represents a 69.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 45,957 shares of company stock worth $29,862,109 over the last quarter. 0.98% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

IDXX has been the subject of a number of research analyst reports. UBS Group dropped their price target on IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating for the company in a research note on Tuesday, February 3rd. Piper Sandler reduced their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a research report on Monday, February 9th. Barclays decreased their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating for the company in a report on Thursday, February 5th. Weiss Ratings lowered shares of IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Thursday, January 29th. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 28th. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $783.33.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $608.41 on Friday. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The firm's 50-day simple moving average is $666.94 and its two-hundred day simple moving average is $668.42. The stock has a market cap of $48.44 billion, a PE ratio of 46.55, a price-to-earnings-growth ratio of 3.70 and a beta of 1.66. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion for the quarter, compared to analysts' expectations of $1.07 billion. During the same quarter in the previous year, the business posted $2.53 earnings per share. IDEXX Laboratories's revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.